Sign in
Not yet taking people in United StatesPhase 1

People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness

Key facts

Who runs it
National Institute of Allergy and Infectious Diseases (NIAID)
Where
Aurora, Baltimore, Birmingham, Boston, Chapel Hill, Chicago, Cincinnati, Cleveland, Columbus, Greensboro, Houston, Los Angeles, Nashville, New York, Newark, Pittsburgh, San Diego, San Francisco, Seattle, Torrance, and Washington D.C., United StatesSee the 24 sites
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
38 people, planned
Starts
1 Feb 2028
Expected to end
26 Oct 2030
Type of study
Interventional
Treatments tested
  • Lenacapavir
  • Cabotegravir
  • Bictegravir/Emtricitabine/Tenofovir Alafenamide
Record updated
16 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Documented HIV-1 infection
  • Prior antiretroviral therapy (ART) experience, including having first been prescribed ART at least 24 weeks prior to enrollment and self-report of prior oral ART use
  • HIV-1 RNA >1000 copies/mL within 60 days prior to study entry
  • Evidence of non-adherence to ART, including virologic failure, poor virologic response, or loss to clinical follow-up with ART non-use/non-adherence
  • At least one reason why NNRTI-based ART is clinically inappropriate, including documented or suspected rilpivirine resistance or prior rilpivirine intolerance
  • Adequate laboratory parameters within 60 days prior to study entry:; Absolute neutrophil count >600/mm3; Hemoglobin ≥7.0 g/dL; Platelet count >50,000/μL; AST and ALT ≤3 × upper limit of normal; Estimated glomerular filtration rate >15 mL/min/1.73 m²
  • For participants of childbearing potential, negative pregnancy test at screening and within 24 hours prior to study entry
  • Ability and willingness to provide informed consent
  • Connected to a medical clinic with access to HIV care and antiretroviral therapy

Who cannot take part

  • Documented integrase strand transfer inhibitor (INSTI) resistance-associated mutations that may compromise cabotegravir activity
  • Prior use of lenacapavir
  • Receipt of HIV immunotherapeutic vaccines or HIV monoclonal antibodies within 6 months prior to study entry
  • Use of prohibited concomitant medications with lenacapavir or cabotegravir within 30 days prior to study entry
  • Active hepatitis B infection, defined as positive hepatitis B surface antigen or detectable hepatitis B virus DNA
  • No suitable injection site for cabotegravir administration due to implants, tattoos, or skin conditions interfering with injection site assessment
  • Serious medical or psychiatric condition
  • Known allergy, hypersensitivity, or intolerance to cabotegravir, lenacapavir, or formulation components
  • Child-Pugh Class C cirrhosis
  • Current pregnancy or breastfeeding

Where in United States

  • University of Colorado Hospital (Site ID: 6101)Aurora, United StatesContact: Nicola HaakonsenNot yet recruiting
  • Johns Hopkins University (Site ID: 201)Baltimore, United StatesContact: Rebecca L BeckerNot yet recruiting
  • Alabama (Site ID: 31788)Birmingham, United StatesContact: Heather LoganNot yet recruiting
  • Brigham and Women's Hospital Therapeutics (BWH TCRS) (Site ID: 107)Boston, United StatesContact: Hannah JordanNot yet recruiting
  • Massachusetts General Hospital (Site ID: 101)Boston, United StatesContact: Amy SbrollaNot yet recruiting
  • Chapel Hill (Site ID: 3201)Chapel Hill, United StatesContact: Erin Elizabeth HoffmanNot yet recruiting
  • Northwestern University (Site ID: 2701)Chicago, United StatesContact: Sherryl L WolfeNot yet recruiting
  • Cincinnati Clinical Research Site (Site ID: 2401)Cincinnati, United StatesContact: Michelle SaemannNot yet recruiting
  • Case Clinical Research Site (Site ID: 2501)Cleveland, United StatesContact: Julie PasternakNot yet recruiting
  • Ohio State University (Site ID: 2301)Columbus, United StatesContact: Lindsay SummersNot yet recruiting
  • Greensboro (Site ID: 3203)Greensboro, United StatesContact: Kelly PhillipsNot yet recruiting
  • Houston Advancing Research Team (Site ID: 31473)Houston, United StatesContact: Maria Laura MartinezNot yet recruiting
  • University of California, Los Angeles CARE Center (Site ID: 601)Los Angeles, United StatesContact: Aleen KhodabakhshianNot yet recruiting
  • Vanderbilt Therapeutics (VT) (Site ID: 3652)Nashville, United StatesContact: Beverly WoodwardNot yet recruiting
  • Columbia Physicians & Surgeons (P&S) (Site ID: 30329)New York, United StatesContact: Brett T GrayNot yet recruiting
  • Weill Cornell Chelsea (Site ID: 7804)New York, United StatesContact: Mauricio VergaraNot yet recruiting
  • Weill Cornell Uptown (Site ID: 7803)New York, United StatesContact: Keisha Ballentine-CargillNot yet recruiting
  • New Jersey Medical School Clinical Research Center (Site ID: 31786)Newark, United StatesContact: Christie Lyn CostanzaNot yet recruiting
  • University of Pittsburgh (Site ID: 1001)Pittsburgh, United StatesContact: Stacey EdickNot yet recruiting
  • UCSD Antiviral Research Center (Site ID: 701)San Diego, United StatesContact: Dawn RosenblumNot yet recruiting
  • University of California, San Francisco (Site ID: 801)San Francisco, United StatesContact: Jay DwyerNot yet recruiting
  • University of Washington Positive Research (Site ID: 1401)Seattle, United StatesContact: Allysson AngeldekaoNot yet recruiting
  • Harbor University of California Los Angeles Center (Site ID: 603)Torrance, United StatesContact: Mario GuerreroNot yet recruiting
  • Whitman-Walker Institute, Inc. (Site ID: 21791)Washington D.C., United StatesContact: Avery WimpelbergNot yet recruiting

About the trial

What the trial wants to find out

This pilot, single-arm, open-label study conducted in the United States will evaluate the efficacy, safety, tolerability, and pharmacokinetics of long-acting lenacapavir plus cabotegravir (LA LEN+CAB) in people with HIV-1 viremia who have a history of non-adherence and confirmed or suspected rilpivirine (RPV) resistance. Participants will be on study for up to 108 weeks.

The group in the trial

  • Long-Acting Lenacapavir Plus Long-Acting CabotegravirTreatment being tested

    Treatment: Lenacapavir, Cabotegravir, and Bictegravir/Emtricitabine/Tenofovir Alafenamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
16 November 2026